Agree Realty Engages Investors at Upcoming ADC Therapeutics Conferences in November 2025
- ADC Therapeutics will engage investors at three significant healthcare conferences in November 2025.
- The company’s flagship product, ZYNLONTA, received FDA and European Commission approvals for treating lymphoma.
- ADC Therapeutics aims to solidify its position as a leader in the ADC field during upcoming conferences.
ADC Therapeutics Prepares for Investor Engagement with Upcoming Conferences
ADC Therapeutics SA, a leader in the development of antibody-drug conjugates (ADCs), is set to increase its visibility and engage with investors through participation in three significant healthcare conferences in November 2025. Chief Executive Officer Ameet Mallik will represent the company at these events, beginning with the Stephens Biotechnology Virtual Fireside Chat on November 3, followed by the Guggenheim Second Annual Healthcare Innovation Conference on November 11 in Boston, and concluding with the Jefferies Global Healthcare Conference on November 19 in London. The company will provide live webcasts for the Guggenheim and Jefferies conferences, enhancing accessibility for stakeholders and allowing for replays for up to 30 days post-event.
The emphasis on investor relations comes at a pivotal time for ADC Therapeutics as it continues to make strides in the ADC landscape. The company's flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has garnered accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after multiple lines of systemic therapy. This success underscores ADC Therapeutics' commitment to addressing significant unmet medical needs in oncology. Furthermore, the company is advancing a next-generation PSMA-targeting ADC, which features an innovative payload and linker, reflecting its dedication to pioneering advancements in cancer treatment methodologies.
With operations based in Lausanne, Switzerland, and additional locations in London and New Jersey, ADC Therapeutics is focused on advancing its ADC technologies from clinical development to commercial launch. The company's strategic approach includes not only developing groundbreaking therapies but also ensuring that these innovations reach the patients who need them most. As the firm prepares for these conferences, it aims to solidify its position as a frontrunner in the ADC field and to communicate its strategic vision and growth potential to investors and industry stakeholders.
In related industry news, Thousand Oaks Biologics, a prominent Asia-based Contract Research, Development, and Manufacturing Organization (CRDMO), is making strides in addressing critical challenges within the ADC field. Their participation in CPHI Frankfurt 2025 highlights their commitment to improving research and development efficiency and scaling up production capabilities. The company’s innovative serum-free media technology enables seamless production scaling, reinforcing its robust quality management system and supporting over 500 biopharmaceutical companies in expediting drug development.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

